Mechanisms of Metabolic Gene Mutations in Cancer

描述（由申请人提供）：在人类癌症中长期观察到代谢调节改变，并广泛用于临床肿瘤检测。最近的两个发现-已经发现三种频繁突变的癌症基因p53、Myc和Ras直接调节参与糖酵解的各种代谢酶的表达。编码四种不同代谢酶的塞文代谢基因在人类癌症中频繁突变，包括富马酸水合酶（FH）、琥珀酸脱氢酶（SDHB、SDHC、SDHD和SDH 5）以及异柠檬酸脱氢酶-1和-2（IDH 1、IDH 2）。靶向IDH 1和IDH 2的肿瘤突变经常发生在神经胶质瘤和白血病中，并分别引起α-酮戊二酸（α-KG）和2-羟基戊二酸（2-HG）产生活性的同时丧失和获得。我们的初步研究表明，2-HG通过结合到催化位点的相同空间并竞争性抑制α-KG依赖性双加氧酶（包括α-KG依赖性组蛋白脱甲基酶和泰特家族5-甲基胞嘧啶羟化酶）的活性而作为α-KG拮抗剂发挥作用。因此，IDH 1/2的突变导致培养细胞和原发性胶质瘤中组蛋白和DNA甲基化的整体改变。我们进一步证明，琥珀酸和富马酸，两种代谢产物，结构上类似于2-HG，并在表达肿瘤衍生的突变体SOH和FH的细胞中积累，类似地抑制组蛋白脱甲基酶在体内和体外。 这些初步研究使我们提出了一种新的和统一的a-KG途径，该途径是这七个代谢基因突变对肿瘤发生的贡献的基础。我们假设多种细胞代谢物可以充当a-KG拮抗剂，并且这些代谢物中任何一种的异常积累都会竞争性抑制a-KG依赖性组蛋白脱甲基酶和泰特羟化酶，导致其活性降低并改变表观遗传控制和细胞命运。结合两名合作研究者在胶质瘤方面的独特临床专业知识和癌症生物信息学方面的计算专业知识，我们提出了三个具体目标，以确定a-KG途径的细胞功能，机制，基因和靶标。 目标1：目的2：探讨SDH和FH基因突变在肿瘤发生中的作用

DESCRIPTION (provided by applicant): Altered metabolic regulation has long been observed in human cancer and broadly used in the clinic for tumor detection. Two recent findings-direct regulation of metabolism by frequently mutated cancer genes and mutations of metabolic enzymes in cancer-have renewed interest in cancer metabolism. Three frequently mutated cancer genes, p53, Myc, and Ras, have been found to directly regulate the expression of various metabolic enzymes involved in glycolysis. Severn metabolic genes encoding for four different metabolic enzymes are frequently mutated in human cancer, including fumarate hydratase (FH), succinate gehygrogenase (SDHB, SDHC, SDHD and SDH5), and isocitrate dehydrogenase-1 and -2 (IDH1, IDH2). Tumor mutations targeting IDH1 and IDH2 occur frequently in gliomas and leukemia and cause simultaneous loss and gain of activities in the production of a-ketoglutarate (a-KG) and 2-hydroxyglutarate (2-HG), respectively. Our preliminary studies demonstrated that 2-HG functions as an a-KG antagonist by binding to the same space in the catalytic site and competitively inhibiting the activity of a-KG-dependent dioxygenases, including both a-KG-dependent histone demethylases and TET family 5-methycytosine hydroxylases. Thus mutation of IDH1/2 leads to global alterations of both histone and DNA methylations in cultured cells and in primary gliomas. We further demonstrate that succinate and fumarate, two metabolites that are structurally similar to 2-HG and are accumulated in cells expressing tumor-derived mutant SOH and FH, similarly inhibit histone demethylases in vivo and in vitro. These preliminary studies have led us to propose a novel and unified a-KG pathway that underlies the contribution to the tumorigenesis by the mutations in these seven metabolic genes. We hypothesize that multiple cellular metabolites can function as a-KG antagonists, and that abnormal accumulation of anyone of these metabolites competitively inhibits a-KG-dependent histone demethylases and TET hydroxylases, leading to their reduced activity and altered epigenetic control and cell fate. Combining the unique clinical expertise in glioma and computational expertise in cancer bioinformatics brought in by two co-investigators, we propose three Specific Aims to determine the cellular function, mechanism, genes and targets of the a-KG pathway. Aim 1: Determine the function of IDH mutations in cell transformation Aim 2: Determine the mechanism of SDH and FH gene mutations in tumorigenesis Aim 3: Elucidate the genes and targets of a-KG pathway